Li J - Search Results

1

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.

Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE, Hidalgo M, Baker SD. Li J, et al. Cancer Biol Ther. 2007 Mar;6(3):432-8. doi: 10.4161/cbt.6.3.3763. Epub 2007 Mar 29. Cancer Biol Ther. 2007. PMID: 17312388

2

Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.

Li J, Zhao M, He P, Hidalgo M, Baker SD. Li J, et al. Clin Cancer Res. 2007 Jun 15;13(12):3731-7. doi: 10.1158/1078-0432.CCR-07-0088. Clin Cancer Res. 2007. PMID: 17575239

3

Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.

Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, Hidalgo M, Baker SD, Donehower RC. Jimeno A, et al. Among authors: li j. J Clin Oncol. 2008 Dec 1;26(34):5504-10. doi: 10.1200/JCO.2008.17.9788. Epub 2008 Oct 27. J Clin Oncol. 2008. PMID: 18955447 Free PMC article. Clinical Trial.

4

Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.

Li J, Jameson MB, Baguley BC, Pili R, Baker SD. Li J, et al. Clin Cancer Res. 2008 Apr 1;14(7):2102-10. doi: 10.1158/1078-0432.CCR-07-1475. Clin Cancer Res. 2008. PMID: 18381951 Clinical Trial.

5

Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach.

Li J, Wu J, Bao X, Honea N, Xie Y, Kim S, Sparreboom A, Sanai N. Li J, et al. Clin Cancer Res. 2017 Dec 15;23(24):7454-7466. doi: 10.1158/1078-0432.CCR-17-0983. Epub 2017 Sep 19. Clin Cancer Res. 2017. PMID: 28928160 Free PMC article. Clinical Trial.

6

Relationship of systemic exposure to unbound docetaxel and neutropenia.

Baker SD, Li J, ten Tije AJ, Figg WD, Graveland W, Verweij J, Sparreboom A. Baker SD, et al. Among authors: li j. Clin Pharmacol Ther. 2005 Jan;77(1):43-53. doi: 10.1016/j.clpt.2004.09.005. Clin Pharmacol Ther. 2005. PMID: 15637530

7

Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma.

Li J, Zhao M, Jimeno A, He P, Ramana Reddy MV, Hidalgo M, Donehower RC, Rudek MA. Li J, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):198-204. doi: 10.1016/j.jchromb.2007.05.047. Epub 2007 Jun 7. J Chromatogr B Analyt Technol Biomed Life Sci. 2007. PMID: 17588831 Free PMC article.

8

Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib.

van Erp NP, Gelderblom H, Karlsson MO, Li J, Zhao M, Ouwerkerk J, Nortier JW, Guchelaar HJ, Baker SD, Sparreboom A. van Erp NP, et al. Among authors: li j. Clin Cancer Res. 2007 Dec 15;13(24):7394-400. doi: 10.1158/1078-0432.CCR-07-0346. Clin Cancer Res. 2007. PMID: 18094422 Clinical Trial.

9

Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).

Huang SM, Li J, Armstrong EA, Harari PM. Huang SM, et al. Among authors: li j. Cancer Res. 2002 Aug 1;62(15):4300-6. Cancer Res. 2002. PMID: 12154033

10

Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade.

Huang SM, Li J, Harari PM. Huang SM, et al. Among authors: li j. Mol Cancer Ther. 2002 May;1(7):507-14. Mol Cancer Ther. 2002. PMID: 12479268

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

176,778 results

Search Page